Current recommendations suggest anti-TNFs as the first-line therapy for RA [188, 189], but TB reactivation risk should be taken into account by clinicians, and in the case of LTBI diagnosis, a non-anti-TNF-α-targeted biologic would probably represent the best choice in terms of efficacy and safety. This evidence concerns the gene TNF and tuberculosis.